


# How Pfizer Scaled Up Manufacturing of Their Breakthrough Vaccine to Help Protect Against the Spread of COVID-19

At Pfizer, we worked at an unprecedented speed to execute one of the most successful manufacturing operations and distribution in history to help prevent COVID-19.



## Manufacturing Capabilities


Pfizer operates one of the most sophisticated supply chain systems in the industry, with more than 40 owned sites and more than 300 suppliers globally.



# An Unprecedented Manufacturing Success

In 2021, Pfizer met its commitment to manufacture more than 3 billion doses of the Pfizer-BioNTech COVID-19 Vaccine worldwide and is expected to manufacture 4 billion doses worldwide in 2022.

Pfizer has manufacturing and distribution sites across the U.S. for the COVID-19 vaccine program, we are leveraging five of them:



## How It Happened

Pfizer's manufacturing and supply chain professionals took several steps to accelerate the scale-up and manufacturing of the vaccine to ensure it was one of the most successful manufacturing operations in history.

- **Exchanging technology** to enable rapid facility, equipment and process design planning
- **Maintaining two parallel supply chains** for appropriate redundancies
- **Modifying facilities** for the vaccine formulations and re-prioritizing capacity
- **Hiring and training staff** to give our operations even more support and flexibility
- **Investing at risk** so we can quickly produce as many doses of vaccine as possible